Shock absorber Patent

Design and development of double acting shock absorber for spacecraft docking operation

Shock absorber operates over wide range

Piston-type hydraulic shock absorber, with a metered damping system, operates over a wide range of kinetic energy loading rates. It is used for absorbing shock and vibration on mounted machinery and heavy earth-moving equipment

Payload accommodations. Avionics payload support architecture

Concepts for vehicle and payload avionics architectures for future NASA programs, including the Assured Shuttle Access program, Space Station Freedom (SSF), Shuttle-C, Advanced Manned Launch System (AMLS), and the Lunar/Mars programs are discussed. Emphasis is on the potential available to increase payload services which will be required in the future, while decreasing the operational cost/complexity by utilizing state of the art advanced avionics systems and a distributed processing architecture. Also addressed are the trade studies required to determine the optimal degree of vehicle (NASA) to payload (customer) separation and the ramifications of these decisions

Panel II

Sanctuary\u27s Reversible Bodies / James Harding, University of Sussex Faulkner\u27s Figures: The Primacy of the Text in The Marionettes / Serena Hagood Blount, University of Alabama The Beam in The Beholder\u27s Eye : Voice and Subjectivity in the Final Section of The Sound and the Fury / C. F. Sanders Creas

Resistance to Opportunities of Plastic Recycling

Plastics present a vast and pressing issue in modern society. Currently recycling efforts fall dangerously short of dealing with even a small percent of the millions of tons of plastic waste produced yearly across the globe. This article investigates resistance toward plastic recycling in three areas from both a contemporary and a historical context, highlighting the magnitude of the problem and the insufficient nature of current solutions. The three primary areas covered are the plastics problem from (1) a design perspective, (2) a material science perspective, and (3) a systems perspective. Solutions are proposed that emphasize a synergistic collaboration across disciplines and research modes. Ultimately, the conclusions point to a need for stronger engagement at the level of people (both consumers and decision makers) and reintegrating reused and recycled plastics into everyday life to build a solid foundation for success

The Priming Function of In-car Audio Instruction

Studies to date have focused on the priming power of visual road signs, but not the priming potential of audio road scene instruction. Here, the relative priming power of visual, audio and multisensory road scene instructions were assessed. In a lab-based study, participants responded to target road scene turns following visual, audio or multisensory road turn primes which were congruent or incongruent to the primes in direction, or control primes. All types of instruction (visual, audio, multisensory) were successful in priming responses to a road scene. Responses to multisensory-primed targets (both audio and visual) were faster than responses to either audio or visual primes alone. Incongruent audio primes did not affect performance negatively in the manner of incongruent visual or multisensory primes. Results suggest that audio instructions have the potential to prime drivers to respond quickly and safely to their road environment. Peak performance will be observed if audio and visual road instruction primes can be timed to co-occur

RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.

Activating mutations in KRAS occur in 32% of lung adenocarcinomas (LUAD). Despite leading to aggressive disease and resistance to therapy in preclinical studies, the KRAS mutation does not predict patient outcome or response to treatment, presumably due to additional events modulating RAS pathways. To obtain a broader measure of RAS pathway activation, we developed RAS84, a transcriptional signature optimised to capture RAS oncogenic activity in LUAD. We report evidence of RAS pathway oncogenic activation in 84% of LUAD, including 65% KRAS wild-type tumours, falling into four groups characterised by coincident alteration of STK11/LKB1, TP53 or CDKN2A, suggesting that the classifications developed when considering only KRAS mutant tumours have significance in a broader cohort of patients. Critically, high RAS activity patient groups show adverse clinical outcome and reduced response to chemotherapy. Patient stratification using oncogenic RAS transcriptional activity instead of genetic alterations could ultimately assist in clinical decision-making

Representing ‘Place’: City Climate Commissions and the Institutionalisation of Experimental Governance in Edinburgh

Against the backdrop of increasingly fragmented and poly-centric urban climate governance, this article examines the establishment of city climate ‘commissions’ as an experimental means of addressing the challenge of climate change at the city-scale. In doing so it addresses the question: What constitutes diversity in voices and perspectives when trying to represent the city as a place for climate action? To answer this question, the article presents an analysis of the Edinburgh Climate Commission’s establishment, drawing on participatory ethnographic research carried out by a researcher embedded within the project team. The account of how this new mode of urban governance was both conceptualised and then put into practice offers a new institutional angle to the literature on urban ‘experimentation.’ Through our reflective analysis we argue that aspirations to ensure pre-defined ‘key’ industries (high carbon emitters) are accounted for in commissioner recruitment, and an over-emphasis on capturing discernible ‘impacts’ in the short term (by involving organisations already pro-active in sustainable development) hindered an opportunity to embrace new perspectives on urban futures and harness the innovative potential of cities to engage with the multifaceted nature of the climate challenge. Furthermore, new insight into the relationship between local authorities and other ‘place-based’ agents of change opens up important questions regarding how to balance the attainment of legitimacy within the political status quo, and the prospect of a new radical politics for urban transformation

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.

PURPOSE: Enhancer of zeste homolog 2 (EZH2) activity is dysregulated in many cancers. PATIENTS AND METHODS: This phase I study determined the safety, maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the intravenously administered, highly selective EZH2 inhibitor, GSK2816126, (NCT02082977). Doses of GSK2816126 ranged from 50 to 3,000 mg twice weekly, and GSK2816126 was given 3-weeks-on/1-week-off in 28-day cycles. Eligible patients had solid tumors or B-cell lymphomas with no available standard treatment regimen. RESULTS: Forty-one patients (21 solid tumors, 20 lymphoma) received treatment. All patients experienced ≥1 adverse event (AE). Fatigue [22 of 41 (53.7%)] and nausea [20 of 41 (48.8%)] were the most common toxicity. Twelve (32%) patients experienced a serious AE. Dose-limiting elevated liver transaminases occurred in 2 of 7 patients receiving 3,000 mg of GSK2816126; 2,400 mg was therefore established as the MTD. Following intravenous administration of 50 to 3,000 mg twice weekly, plasma GSK2816126 levels decreased biexponentially, with a mean terminal elimination half-life of approximately 27 hours. GSK2816126 exposure (maximum observed plasma concentration and area under the plasma-time curve) increased in a dose-proportional manner. No change from baseline in H3K27me3 was seen in peripheral blood mononuclear cells. Fourteen of 41 (34%) patients had radiological best response of stable disease, 1 patient with lymphoma achieved a partial response, 21 of 41 (51%) patients had progressive disease, and 5 patients were unevaluable for antitumor response. CONCLUSIONS: The MTD of GSK2816126 was established at 2,400 mg, but the dosing method and relatively short half-life limited effective exposure, and modest anticancer activity was observed at tolerable doses